Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp WT (NQ: LEXXW )

1.240 -0.240 (-16.22%)
Streaming Delayed Price Updated: 12:52 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,141
Open 1.250
Bid (Size) 1.120 (2)
Ask (Size) 1.360 (40)
Prev. Close 1.480
Today's Range 1.240 - 1.400
52wk Range 0.0500 - 2.500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Via ACCESSWIRE

Performance

YTD
+148.00%
+148.00%
1 Month
+21.94%
+21.94%
3 Month
-8.15%
-8.15%
6 Month
+47.62%
+47.62%
1 Year
+352.89%
+352.89%

More News

Read More
Lexaria Preparing For Strategic Growth
Via ACCESSWIRE
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
Via ACCESSWIRE
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Via ACCESSWIRE
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Via ACCESSWIRE
Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
Via ACCESSWIRE
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
Via ACCESSWIRE
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
Via ACCESSWIRE
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
Via ACCESSWIRE
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Via ACCESSWIRE
Lexaria Awarded New Patents
Via ACCESSWIRE
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
Via ACCESSWIRE
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Via ACCESSWIRE
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.